Bal Pharma Share Price Today (BALPHARMA)
TODAY IN ONE LINE
BALPHARMA fell 1.8% on light volume, in line with Nifty's -0.8% move.
With a market cap of ₹140.33 Cr., it trades at a P/E of N/A. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Bal Pharma flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●High Promoter HoldingPromoters hold 50.9% skin-in-the-game
- ●Steady Dividend YieldReliable 1.32% dividend yield
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.02x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Earnings DeclineEPS (TTM) has contracted by 33.5% YoY
- ●Poor Capital ReturnsLow ROE of 7.9%
Latest Bal Pharma News
What changed recently?
Recent events, corporate actions, and announcements.
Bal Pharma Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Bal Pharma Limited, framed against the sector median so the premium or discount is obvious at a glance.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
Bal Pharma Limited technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Bal Pharma Limited — derived from the live tape, not yesterday's close.
Bal Pharma Limited last traded at ₹87.66 with an intraday range of ₹87.65–₹89.94 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹87.66| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 93.76 | +6.10 | +6.96% |
| R3 | 91.47 | +3.81 | +4.35% |
| R2 | 90.71 | +3.05 | +3.48% |
| R1 | 89.18 | +1.52 | +1.74% |
| PIVOT | 88.42 | 0.76 | 0.86% |
| CURRENT | 87.66 | — | — |
| S1 | 86.89 | -0.77 | -0.87% |
| S2 | 86.13 | -1.53 | -1.75% |
| S3 | 84.60 | -3.06 | -3.49% |
| S4 | 82.31 | -5.35 | -6.10% |
BALPHARMA is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹87.8–₹89.94
Trading Below opening range, showing Bearishness
Bal Pharma Limited financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for Bal Pharma Limited — consolidated or standalone — with margins, YoY growth and key ratios inline.
Bal Pharma Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹140.33 Cr. and reported EPS of ₹3.95.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 303 | 312 ▲ 2.8% |
| Sales Growth YoY %Derived | -10.65% | 2.83% |
| Other Income | 2 | 2 ▼ 12.5% |
| Total Income | 305 | 314 ▲ 2.7% |
| 158 | 158 ▲ 0.0% | |
| Gross ProfitDerived | 145 | 154 ▲ 5.9% |
| Gross Margin %Derived | 47.90% | 49.32% |
| 116 | 122 ▲ 5.3% | |
| EBITDA (Operating Profit)Derived | 30 | 32 ▲ 7.9% |
| OPM %Derived | 9.75% | 10.24% |
| 27 | 28 ▲ 4.8% | |
| Profit Before Tax (PBT) | 5 | 6 ▲ 15.5% |
| -2 | -0 ▲ 81.6% | |
| Effective Tax %Derived | -40.87% | -6.51% |
| Total Profit for Period | 7 | 6 ▼ 12.2% |
| Less: Non-controlling Interests | 0 | 0 ▲ 71.4% |
| Net Profit (Owner's PAT)Derived | 7 | 6 ▼ 12.5% |
| Net Profit Margin %Derived | 2.37% | 2.02% |
| PAT Growth YoY %Derived | -2.86% | -12.46% |
| Earnings Per Share (EPS ₹) | 4.53 | 3.95 ▼ 12.8% |
| Diluted Shares Outstanding (Cr) | 2 | 2 ▲ 0.0% |
| Share of Profit from Associates/JVs | -0 | — ▲ 100.0% |
| Other Comprehensive Income (Net of Tax) | — | 0 |
| Total Expenses (incl. D&A & Interest) | 300 | 308 ▲ 2.5% |
| Material Cost % of RevenueDerived | 49.45% | 51.65% |
| Employee Cost % of RevenueDerived | 20.59% | 21.33% |
| Other Cost % of RevenueDerived | 17.56% | 17.75% |
| Interest Coverage (x)Derived | 1.17x | 1.24x |
| Period | Mar 2018 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 212 | 171 ▼ 19.2% | 251 ▲ 46.4% | 281 ▲ 12.2% | 304 ▲ 8.2% | 339 ▲ 11.5% | 303 ▼ 10.7% | 312 ▲ 2.8% | |
| Sales Growth YoY %Derived | — | — | 46.43% | 12.25% | 8.18% | 11.51% | -10.65% | 2.83% | |
| Other Income | 2 | 2 ▲ 16.8% | 1 ▼ 38.1% | 5 ▲ 352.6% | 1 ▼ 81.7% | 3 ▲ 202.8% | 2 ▼ 22.7% | 2 ▼ 12.5% | |
| Total Income | 213 | 173 ▼ 18.9% | 252 ▲ 45.5% | 286 ▲ 13.8% | 305 ▲ 6.6% | 342 ▲ 12.1% | 305 ▼ 10.8% | 314 ▲ 2.7% | |
99 | 84 ▼ 15.3% | 151 ▲ 79.4% | 168 ▲ 11.0% | 173 ▲ 3.1% | 192 ▲ 11.0% | 158 ▼ 17.7% | 158 ▲ 0.0% | ||
| Gross ProfitDerived | 112 | 87 ▼ 22.6% | 100 ▲ 14.5% | 114 ▲ 14.2% | 131 ▲ 15.6% | 147 ▲ 12.2% | 145 ▼ 1.5% | 154 ▲ 5.9% | |
| Gross Margin %Derived | 53.08% | 50.83% | 39.75% | 40.43% | 43.21% | 43.47% | 47.90% | 49.32% | |
95 | 82 ▼ 13.5% | 75 ▼ 8.6% | 90 ▲ 20.1% | 106 ▲ 17.9% | 116 ▲ 9.0% | 116 ▼ 0.3% | 122 ▲ 5.3% | ||
| EBITDA (Operating Profit)Derived | 17 | 5 ▼ 72.6% | 24 ▲ 413.8% | 23 ▼ 4.0% | 25 ▲ 7.0% | 32 ▲ 25.5% | 30 ▼ 6.2% | 32 ▲ 7.9% | |
| OPM %Derived | 8.19% | 2.78% | 9.76% | 8.35% | 8.26% | 9.29% | 9.75% | 10.24% | |
16 | 20 ▲ 25.5% | 21 ▲ 6.8% | 19 ▼ 9.5% | 21 ▲ 9.6% | 25 ▲ 18.8% | 27 ▲ 5.1% | 28 ▲ 4.8% | ||
| Profit Before Tax (PBT) | 3 | -14 ▼ 569.3% | 4 ▲ 130.3% | 9 ▲ 123.8% | 5 ▼ 48.3% | 9 ▲ 90.5% | 5 ▼ 43.2% | 6 ▲ 15.5% | |
3 | -1 ▼ 125.4% | -1 ▲ 4.4% | 3 ▲ 670.5% | 2 ▼ 38.8% | 2 ▼ 24.8% | -2 ▼ 231.1% | -0 ▲ 81.6% | ||
| Effective Tax %Derived | 86.94% | 4.71% | -14.86% | 37.87% | 44.84% | 17.70% | -40.87% | -6.51% | |
| Total Profit for Period | 0 | -13 ▼ 3524.1% | 5 ▲ 136.6% | 6 ▲ 21.1% | 3 ▼ 54.1% | 7 ▲ 184.3% | 7 ▼ 3.3% | 6 ▼ 12.2% | |
| Less: Non-controlling Interests | — | — | -0 | 0 ▲ 409.3% | — ▼ 100.0% | 0 | 0 ▼ 60.2% | 0 ▲ 71.4% | |
| Net Profit (Owner's PAT)Derived | 0 | -13 ▼ 3524.1% | 5 ▲ 136.8% | 6 ▲ 18.3% | 3 ▼ 53.3% | 7 ▲ 182.2% | 7 ▼ 2.9% | 6 ▼ 12.5% | |
| Net Profit Margin %Derived | 0.18% | -7.53% | 1.89% | 2.00% | 0.86% | 2.18% | 2.37% | 2.02% | |
| PAT Growth YoY %Derived | — | — | 136.79% | 18.32% | -53.32% | 182.21% | -2.86% | -12.46% | |
| Earnings Per Share (EPS ₹) | 0.27 | -9.10 ▼ 3470.4% | 3.20 ▲ 135.2% | 3.78 ▲ 18.1% | 1.67 ▼ 55.8% | 4.68 ▲ 180.2% | 4.53 ▼ 3.2% | 3.95 ▼ 12.8% | |
| Diluted Shares Outstanding (Cr) | 1 | 1 ▲ 0.0% | 1 ▲ 4.6% | 1 ▲ 0.0% | 2 ▲ 5.9% | 2 ▲ 0.7% | 2 ▲ 0.7% | 2 ▲ 0.0% | |
| Share of Profit from Associates/JVs | — | — | — | — | — | — | -0 | — ▲ 100.0% | |
| Other Comprehensive Income (Net of Tax) | -0 | -0 ▼ 20.9% | 0 ▲ 170.4% | 0 ▼ 98.5% | — ▼ 100.0% | 0 | — ▼ 100.0% | 0 | |
| Total Expenses (incl. D&A & Interest) | 210 | 186 ▼ 11.4% | 248 ▲ 32.8% | 277 ▲ 12.0% | 300 ▲ 8.4% | 333 ▲ 10.9% | 300 ▼ 9.9% | 308 ▲ 2.5% | |
| Material Cost % of RevenueDerived | 48.62% | 42.20% | 54.07% | 58.32% | 58.90% | 53.53% | 49.45% | 51.65% | |
| Employee Cost % of RevenueDerived | 22.28% | 29.47% | 16.72% | 16.80% | 18.18% | 17.80% | 20.59% | 21.33% | |
| Other Cost % of RevenueDerived | 22.60% | 18.58% | 13.27% | 15.28% | 16.77% | 16.38% | 17.56% | 17.75% | |
| Interest Coverage (x)Derived | 1.14x | -0.23x | 1.25x | 1.39x | 1.31x | 1.41x | 1.17x | 1.24x |
Bal Pharma segment analysis : revenue and profit mix.
Disclosed business segments at Bal Pharma with their share of revenue and profit, switchable between consolidated and standalone reporting.
Bal Pharma discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Bal Pharma Limited.
Our AI distills the core fundamental drivers supporting Bal Pharma Limited, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
Bal Pharma Limited's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Promoter holding 50.86% signals strong long-term management commitment and stability.
Dividend yield 1.54% provides steady income for conservative investors seeking returns.
P/E ratio 20.36x appears undervalued relative to broader pharmaceutical sector multiples.
Broad product portfolio across 30+ countries enables geographic revenue diversification.
Low beta 0.90 indicates defensive characteristics during market volatility periods.
Key Risks.
Latest quarterly EPS declined 46.6% YoY despite revenue growth, signaling profitability stress.
TTM EPS declined 33.5% YoY, indicating sustained earnings momentum deterioration.
Latest quarterly sales declined 11.40% YoY, showing weakening domestic demand pressures.
Latest quarterly net profit declined 19.20% YoY, compounding profitability concerns significantly.
Net debt ₹151.55 Cr represents 143% of FY2026 net profit, creating refinancing risk.
Flip Conditions.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 2.44. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
Income thesis breaks if the dividend is cut or yield falls below 0.66%.
Bal Pharma Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Bal Pharma Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Bal Pharma Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Bal Pharma Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
- 1Pick how to scan. Detection sets sensitivity — Daily (standard) → Weekly (big swings). History sets how far back to look.
- 2Read the summary. The tiles at the top give the current read: net bias, the strongest pattern, and the one nearest to triggering.
- 3Scan the list. Use the Actionable, Watchlist, and History tabs to browse patterns. Click a pattern card to focus it.
- 4Inspect on the chart. Focusing draws the pattern’s pivots plus its break (blue), target (amber) and invalidation lines.
- 5Filter to what matters. Use the status controls (Confirmed, Forming, Invalidated) to hide noise and find exactly what you are looking for.
Pattern history — every completed pattern and its outcome
Bal Pharma Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Bal Pharma Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Bal Pharma Limited stood at 63.8% of traded volume, against a 20-day average of 61.3%.
Bal Pharma announcements: results, concalls, ratings, M&A.
Filings Bal Pharma sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Bal Pharma files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 39 documents below.
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Bal Pharma Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Shareholders meeting
Bal Pharma Limited has informed the Exchange regarding Notice of Postal Ballot for consider the issue of 10,00,000 Warrants to Mr. Shailesh Siroya ,…
Trading Window
Bal Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Statement of deviation(s) or variation(s) under Reg. 32
Bal Pharma Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32
Resignation of Director/KMP/SMP
Bal Pharma Limited has informed the Exchange about Resignation of Director/KMP/SMP
Bal Pharma dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Bal Pharma has declared, sequenced by announce and record date.
Bal Pharma corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Bal Pharma Limited: business, sector, key facts.
What Bal Pharma Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Bal Pharma Limited operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: BALPHARMA, BSE: 524824.
Bal Pharma Limited is a pharmaceutical company headquartered in Bengaluru, India, that manufactures and markets a diverse range of pharmaceutical formulations and active pharmaceutical ingredients (APIs) both domestically and internationally. Their product portfolio caters to a broad spectrum of therapeutic areas and consumer needs.
The company's offerings include a wide array of prescription drugs, generic medications, over-the-counter (OTC) products, and intravenous infusion products. This encompasses various therapeutic categories such as anti-infectives, pain management solutions, respiratory care medications, and women's health products, marketed under various brand names including Aziwin, Ebay, Balvibe, MNF, Ocium, and Monogesic Plus Gel. They also produce diabetic care products (Diabend and Diabend M Group), herbal/ayurvedic preparations for conditions like prostate enlargement, renal calculi, and infertility (Stonex, Ashwamed, Prostowin, Suswas, Menoleap, and Ayursulin), and products addressing cardiovascular health, skin care, and bone health (Secremet and Servace brands).
Beyond finished formulations, Bal Pharma is a significant player in the API market, providing a wide array of active ingredients for numerous therapeutic applications. These APIs support the production of medications targeting conditions such as allergies, inflammation, diabetes, neurological disorders, urinary issues, and acne. The company manufactures diverse dosage forms including tablets, capsules, syrups, suspensions, ophthalmic preparations, creams, and ointments.
Furthermore, Bal Pharma's expertise extends to the treatment of gastrointestinal disorders and conditions like piles, fistula, and constipation. The company's international reach is substantial, with exports spanning approximately 30 countries. Established in 1987, Bal Pharma has grown to become a prominent player in the Indian and global pharmaceutical landscape.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs and Pharmaceuticals (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Bal Pharma Limited (BALPHARMA).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Bal Pharma Limited (BALPHARMA)?
The current share price of Bal Pharma Limited (BALPHARMA) is ₹87.66. Today, the stock has declined by ₹1.60 (1.79%), trading in a range of ₹87.65 to ₹89.94. The stock opened at ₹89.94 with a trading volume of 11,365 shares.
02What is the 52-week high and low price of Bal Pharma Limited stock?
The 52-week high price of Bal Pharma Limited (BALPHARMA) is ₹102.99, while the 52-week low is ₹60. Currently trading at ₹87.66, the stock is 64.3% away from its 52-week low and 14.9% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
03What is the dividend yield of Bal Pharma Limited and when is the next dividend?
Bal Pharma Limited offers a dividend yield of 1.32%, which means for every ₹100 invested at the current price of ₹87.66, you can expect to receive approximately ₹1.32 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
04How is Bal Pharma Limited stock performing today in the market?
Bal Pharma Limited stock opened at ₹89.94 and is currently trading at ₹87.66, showing a decline of ₹1.60 (1.79%). The intraday high is ₹89.94 and low is ₹87.65. The trading volume stands at 11,365 shares, indicating moderate market participation today.
05What is the market capitalization of Bal Pharma Limited?
Bal Pharma Limited has a market capitalization of ₹140.33 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹87.66) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
06What is the ROE and ROCE of Bal Pharma Limited?
Bal Pharma Limited has a Return on Equity (ROE) of 7.87% and Return on Capital Employed (ROCE) of 9.69%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
07Which sector and industry does Bal Pharma Limited belong to?
Bal Pharma Limited operates in the Healthcare sector and belongs to the Pharmaceuticals industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
08What is the debt-to-equity ratio of Bal Pharma Limited?
Bal Pharma Limited has a debt-to-equity ratio of 1.94, which measures the company's financial leverage by comparing total debt to shareholders' equity. A ratio above 1 suggests the company uses more debt than equity for financing. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
The data, ratios and commentary about Bal Pharma Limited (BALPHARMA) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.